Ainos, Inc. (FZX.F)
- Previous Close
2.6000 - Open
-- - Bid --
- Ask --
- Day's Range
-- - 52 Week Range
2.4850 - 3.7900 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
0 - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
www.ainos.comRecent News: FZX.F
Performance Overview: FZX.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FZX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FZX.F
Valuation Measures
Market Cap
5.96M
Enterprise Value
9.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.03
Price/Book (mrq)
0.48
Enterprise Value/Revenue
79.92
Enterprise Value/EBITDA
-1.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.42%
Return on Equity (ttm)
-46.62%
Revenue (ttm)
122.11k
Net Income Avi to Common (ttm)
-13.77M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.89M
Total Debt/Equity (mrq)
23.29%
Levered Free Cash Flow (ttm)
948.64k
Company Insights: FZX.F
FZX.F does not have Company Insights